Investigational New Drugs

, Volume 24, Issue 3, pp 213–221 | Cite as

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

  • Patrapim Sunpaweravong
  • Lyn Magree
  • Rachel Rabinovitch
  • Paul Bunn
  • Karen KellyEmail author
Phase I Studies


Limited stage small cell lung cancer (LS-SCLC) is an infrequent but aggressive tumor. No major advances in the treatment of this disease have been achieved in recent years. This study was conducted to determine the maximum-tolerated dose (MTD) and efficacy of docetaxel, etoposide, and carboplatin (DEC) given before definitive chest radiotherapy with concurrent cisplatin and etoposide. Seventeen untreated LS-SCLC patients received docetaxel 50 mg/m2, etoposide 50–80 mg/m2, and carboplatin AUC = 5–6, intravenously on day 1 followed by etoposide 100–160 mg/m2 orally on days 2 and 3 every 21 days for two cycles followed by once daily radiotherapy to a total dose of 50 Gy given concurrently with cisplatin (60 mg/m2, d1) and etoposide (120 mg/m2, d1 and 240 mg/m2 day 2–3) for 2 cycles. All patients were assessable for toxicity and 15 for response. The most frequent toxicity was grade 3 and 4 neutropenia in 41% of patients during DEC and in 57% with chemoradiation. The MTD for DEC was docetaxel 50 mg/m2 plus carboplatin AUC = 5 and etoposide 50/100 mg/m2 with growth factor support. Significant nonhematologic toxicities were primarily radiation-related esophagitis (43%). One patient (6%) died from toxicity. The overall response rate was 82% with 10 patients (59%) achieving a complete response. The median survival was 12.1 months (95% CI, 6.4–17.8 months) and the 1-year survival rate was 47%. This novel approach produced similar efficacy results to current two drug regimens but was associated with significant neutropenia. Alternative strategies to increase complete response rates and survival are needed.

Key Words

docetaxel triple drug chemotherapy limited stage small cell lung cancer clinical trial 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer Thun MJ: Cancer Statistics 2004 CA. A Cancer Journal for Clinicians 54: 8–29, 2004CrossRefGoogle Scholar
  2. 2.
    Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RI, Brodin O, Joss RA, Kies MS, Lebeau B, et al.: A meta-analysis of thoracic radiotherapy for small cell lung cancer. New Engl J Med 327: 1618–1624, 1992PubMedCrossRefGoogle Scholar
  3. 3.
    Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890–895, 1992PubMedGoogle Scholar
  4. 4.
    Turrisi AT, Kyungmann K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH: Twice-daily compared with once daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271, 1999CrossRefPubMedGoogle Scholar
  5. 5.
    Kelly K: New chemotherapy agents for small cell lung cancer. Chest 117(4 Suppl 1): 156S–62S, 2000CrossRefPubMedGoogle Scholar
  6. 6.
    Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A(8): 1058–1060, 1994CrossRefPubMedGoogle Scholar
  7. 7.
    Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA: Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13(4): 343–345, 1996CrossRefPubMedGoogle Scholar
  8. 8.
    Hesketh PJ, Crowley JJ, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livington RB, Gandara DR: Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 5(4): 237–41, 1999PubMedGoogle Scholar
  9. 9.
    Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouva G: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5(7): 601–7, 1994PubMedGoogle Scholar
  10. 10.
    Bunn PA Jr, Kelly K: A phase I study of cisplatin, etoposide and paclitaxel in small cell lung cancer: A University of Colorado Cancer Center Study. Sem Oncol 22(Suppl 12): 54–58, 1995Google Scholar
  11. 11.
    Neill HB, Miller AA, Clamon GH, Perry MC, Crawford J, Green MR: A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin Oncol 24(4 Suppl 12): S12-130–S12-134, 1997Google Scholar
  12. 12.
    Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11): 1748–1756, 1989PubMedGoogle Scholar
  13. 13.
    Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10(4): 239–253, 1992CrossRefPubMedGoogle Scholar
  14. 14.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr: A phase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer. Clin Can Res 5: 3419–3424, 1999Google Scholar
  15. 15.
    Kelly K, Lovato L, Bunn PA Jr, Livington RB, Zangmeister J, Taylor SA, Roychodhury D, Crowley JJ, Gandara Dr: Cisplatin, etoposide, and paclitaxel with granulocyte colony stimulating factor in untreated patients with extensive stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Can Res 2325–2329, 2001Google Scholar
  16. 16.
    Neill HB, Herndon JE II, Miller AA, Watson DM, Sanlder AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR: Cancer and Leukemia Group: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23: 3752–3759, 2005Google Scholar
  17. 17.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12: 463–470, 2001CrossRefPubMedGoogle Scholar
  18. 18.
    Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins I, Thomas M, Greco FA: Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 15: 3464–3470, 1997PubMedGoogle Scholar
  19. 19.
    Vieitez JM, Valladares M, Gracia M, Gonzalez-Baron M, Martin G, Mel JR, Rodriguez R, Constenia M, Gomez Aldavari JL, Dominguez S, Dorta J, Garcia-Giron C, Lopez R, Sevilla I, Esteban E, Anton LM, Pelaez I, Lopez E, Lacave AJ: Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small cell lung cancer. Lung Cancer 39: 77–84, 2003CrossRefPubMedGoogle Scholar
  20. 20.
    Reck M, Jagos U, Grunwald F, Kaukel E, Koschel G, von Pawel J, Hessler S, Gatzemeier U: Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—A phase II study. Lung Cancer 39: 63–69, 2003CrossRefPubMedGoogle Scholar
  21. 21.
    Sandler A, Declerk L, Wagner H, Levitan N, DeVore R, Levitt M, Johnson D: A phase II study of cisplatin (P) plus etoposide (E) plus paclitaxel (P) (PET) and concurrent radiation therapy for previously untreated limited stage small-cell lung cancer (SCLC) (E2496) (abstr): An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 19: 491a, 2000Google Scholar
  22. 22.
    Ettinger DS, Seiferheld WF, Abrams RA, Fontanesi J, Machtay M, Duncan P, Curran W, Byhardt R: Cisplatin (P), etoposide (E), paclitaxel (P), and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (Ps) with limited disease (LD) small cell lung cancer (SCLC) (abstr): Preliminary results of RTOG 96-09. Proc Am Soc Clin Oncol 19: 490a, 2000Google Scholar
  23. 23.
    Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick SC, Chang A, Johnson D: Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small cell lung carcinoma. J Clin Oncol 18: 1102–1109, 2000PubMedGoogle Scholar
  24. 24.
    Bremnes RM, Sundstrom S, Vilsvik J, Aasebo U: Multicenter phaseII trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small cell lung cancer. J Clin Oncol 19: 3532–3538, 2001PubMedGoogle Scholar
  25. 25.
    Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR: Phase II Trial of cisplatin/Etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 22: 127–132, 2004CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2005

Authors and Affiliations

  • Patrapim Sunpaweravong
    • 1
    • 2
  • Lyn Magree
    • 1
  • Rachel Rabinovitch
    • 3
  • Paul Bunn
    • 1
  • Karen Kelly
    • 1
    Email author
  1. 1.Division of Medical OncologyUniversity of Colorado Cancer CenterAuroraUSA
  2. 2.Prince of Songkla UniversitySongklaThailand
  3. 3.Department of Radiation OncologyUniversity of Colorado Cancer CenterAuroraUSA

Personalised recommendations